Monthly Archives: November 2018

Fibromyalgia Research

Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? A recent literature review was completed to show that there may be an underlying clinical endocannabinoid deficiency that may be suitably treated with cannabinoid medicines. These scientists conclude this by analyzing literature about migraine headache, IBS and other related common fibromyalgia symptoms.